Home

Marco Taglietti

CIK 1408870 · Chief Executive Officer · last filed 2026-06-12

Marco Taglietti is a Chief Executive Officer who has filed 74 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for AQST, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$1.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $260.1K across reported positions. 26 SEC filings were submitted jointly with FOREST LABORATORIES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$260.1K

Companies

5

Total Filings

74

Lifetime Open-Market Net

$1.57M

Filer Profile

Reported Address
C/O FOREST LABORATORIES, INC.
909 THIRD AVENUE
NEW YORK, NY 10022
Related Filers
FOREST LABORATORIES INC — 26 joint filings, latest 2014-07-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AQST Director — $4.78 — $0 7 2026-06-12
SCYX Chief Executive Officer 34,008 $4.84 $164.6K $2.13M 35 2022-04-28
DCTH Director 6,001 $15.91 $95.5K $106.8K 6 2020-05-08
NephroGenex, Inc. (NRX) Delisted Director — — — $0 2 2015-05-04
Forest Laboratories, LLC (FRX) Delisted EVP-Drug Dev & Ch.Medical Off. 100,486 $12.00 $1.21M -$663.9K 23 2013-12-10

Recent Filings

74 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 AQST Grant (A) — $0 EDGAR
2025-06-12 AQST Grant (A) — $0 EDGAR
2024-06-21 AQST Grant (A) — $0 EDGAR
2023-06-23 AQST Grant (A) — $0 EDGAR
2022-06-24 AQST Grant (A) — $0 EDGAR
2022-04-28 SCYX Mixed +75,000 $225.0K EDGAR
2022-02-08 SCYX Grant (A) +87,200 $0 EDGAR
2021-06-17 AQST Grant (A) — $0 EDGAR
2021-03-15 AQST Grant (A) — $0 EDGAR
2021-02-02 SCYX Grant (A) — $0 EDGAR
Showing 1–10 of 74
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.